DDInter1826 DDInter706
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Exenatide
Tolazamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dobutamine
Dobutamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tagraxofusp
Tagraxofusp {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Tolazamide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Tolazamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Tolazamide {u} (Compound) binds {v} (Gene) KCNJ1
KCNJ1 {u} (Gene) is bound by {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Tolazamide {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Tolazamide {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Exenatide
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Exenatide
Tolazamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp and Tagraxofusp may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Tolazamide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Tolazamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Tolazamide (Compound) binds KCNJ1 (Gene) and KCNJ1 (Gene) is bound by Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Tolazamide (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Tolazamide (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Exenatide